SCHEMBL7066247

SCHEMBL7066247

CC1(C)O[C@@H]2[C@@H](OCc3ccccc3)O[C@H](CO)[C@@H](N)[C@@H]2O1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.39
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDE4D Q08499 2/20 0.37
LGALS8 O00214 1/20 0.36
ALDH1A1 P00352 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SSTR1 P30872 1/20 0.34
SSTR2 P30874 1/20 0.34
SSTR4 P31391 1/20 0.34
SSTR3 P32745 1/20 0.34
SSTR5 P35346 1/20 0.34
GJB2 P29033 1/20 0.34
PTPN1 P18031 1/20 0.34
CDC25B P30305 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6701050 0.90 SLC6A2 (0.41) SLC6A2TSHRCYP2C19PDE4DLGALS8
SCHEMBL6864596 0.90 SLC6A2 (0.41) SLC6A2TSHRCYP2C19PDE4DLGALS8
SCHEMBL7156144 0.90 SLC6A2 (0.41) SLC6A2TSHRCYP2C19PDE4DLGALS8
SCHEMBL6704224 0.90 SLC6A2 (0.41) SLC6A2TSHRCYP2C19PDE4DLGALS8
SCHEMBL7154227 0.81 SLC6A2 (0.44) SLC6A2TSHRCYP2C19PDE4DLGALS8
SCHEMBL7642620 0.81 SLC6A2 (0.44) SLC6A2TSHRCYP2C19PDE4DLGALS8
SCHEMBL7066725 0.79 SLC6A2 (0.37) SLC6A2TSHRCYP2C19PDE4DLGALS8
SCHEMBL7064868 0.78 LGALS8 (0.42) TSHRLGALS8ALDH1A1
SCHEMBL10575985 0.78 MEN1 (0.39) CYP2C19PDE4DALDH1A1MEN1KMT2A
SCHEMBL21243724 0.78 MEN1 (0.48) ALDH1A1MEN1KMT2APTPN1CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236229-A1 Novel 3,5,and/or 6 substituted analogues of swainsonine processes for their preparation and their use as therapeutic agents GLYCODESIGN INC. (CA) 2003-12-25 US disclosed
US-20020099065-A1 Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents GLYCODESIGN INC. (CA) 2002-07-25 US disclosed
US-6048870-A MANNOSIDASE INHIBITOR; IMMUNOSTIMULANT GLYCODESIGN (CA) 2000-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236229-A1 Novel 3,5,and/or 6 substituted analogues of swainsonine processes for their preparation and their use as therapeutic agents WDR77, WDR3, WDR5 SLC6A2 1586/4885TSHR 4771/4885CYP2C19 4312/4885
US-20020099065-A1 Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents WDR5, WDR3, WDR77 SLC6A2 563/4885TSHR 4315/4885CYP2C19 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.